Corbus Pharmaceuticals Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia have jointly filed a Schedule 13G, reporting no beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. common stock as of March 31, 2026.
NASDAQ
Octagon Capital Advisors LP, along with Octagon Investments Master Fund LP and Ting Jia, reported a 5.4% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. as of December 31, 2025.
NASDAQ
abrdn Inc. and its parent Aberdeen Group plc have reported a beneficial ownership of 7.53% in Corbus Pharmaceuticals Holdings, Inc. common stock.
NASDAQ
SCHEDULE 13G/A: Cormorant Asset Management Discloses 13.36% Corbus Stake
Cormorant Asset Management and Bihua Chen have disclosed a 13.36% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc. common stock.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have disclosed a 12.82% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc., holding 2,375,000 shares.
NASDAQ
Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 5.3% in Corbus Pharmaceuticals Holdings, Inc.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.89% in Corbus Pharmaceuticals Holdings Inc. common stock as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 2.9% Passive Stake in Corbus Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.9% beneficial ownership stake in Corbus Pharmaceuticals Holdings Inc. as of June 30, 2025.
NASDAQ
OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed an amendment to their Schedule 13G, disclosing an aggregate beneficial ownership of 9.6% in Corbus Pharmaceuticals Holdings, Inc. as of December 31, 2024.